Alpharen™ Tablets (Fermagate Tablets):
Alpharen Tablets, a calcium-free non-absorbed phosphate binder, is in Phase 3 development in the U.S. and in Europe for the treatment of hyperphosphatemia in dialysis patients. The available Phase 3 data show that Alpharen controls elevated serum phosphorus at least as well as sevelamer and lanthanum, the market leaders in the U.S. and Europe, respectively, without unwanted heavy metal accumulation in the bone. The required dosage is nearly 40% lower than that of sevelamer, reducing the “pill burden” and increasing dosing compliance. Further Phase 3 development will start in 1H‘16. Alpharen is protected by issued composition of matter patents through 2018, by manufacturing patents through 2029, and by pending and planned use patent applications thereafter.